NCT06880549View on ClinicalTrials.gov

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

January 10, 2029

Study Completion Date

January 10, 2029

Conditions
Advanced Solid Tumors
Interventions
BIOLOGICAL

mRNA-4106

Intramuscular Injection

BIOLOGICAL

Nivolumab/Relatlimab

Intravenous infusion

Trial Locations (3)

49546

RECRUITING

START Midwest, Grand Rapids

78229

RECRUITING

START San Antonio, San Antonio

84119

RECRUITING

START Mountain Region, West Valley City

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY

NCT06880549 - A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | Biotech Hunter | Biotech Hunter